280 related articles for article (PubMed ID: 29702606)
21. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow-derived hematopoietic stem cell transplantation: a 1-year follow-up.
Deda H; Inci MC; Kürekçi AE; Sav A; Kayihan K; Ozgün E; Ustünsoy GE; Kocabay S
Cytotherapy; 2009; 11(1):18-25. PubMed ID: 19012065
[TBL] [Abstract][Full Text] [Related]
22. Adjuvant Lineage-Negative Cell Therapy as a Potential Silencer of the Complement-Mediated Immune System in ALS Patients.
Sobuś A; Baumert B; Gołąb-Janowska M; Kulig P; Paczkowska E; Łuczkowska K; Rogińska D; Zawiślak A; Milczarek S; Osękowska B; Pawlukowska W; Meller A; Machowska-Sempruch K; Wełnicka A; Nowacki P; Machaliński B
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830531
[TBL] [Abstract][Full Text] [Related]
23. Stem cell transplantation for amyotrophic lateral sclerosis.
Baloh RH; Glass JD; Svendsen CN
Curr Opin Neurol; 2018 Oct; 31(5):655-661. PubMed ID: 30080719
[TBL] [Abstract][Full Text] [Related]
24. Intrathecal application of neuroectodermally converted stem cells into a mouse model of ALS: limited intraparenchymal migration and survival narrows therapeutic effects.
Habisch HJ; Janowski M; Binder D; Kuzma-Kozakiewicz M; Widmann A; Habich A; Schwalenstöcker B; Hermann A; Brenner R; Lukomska B; Domanska-Janik K; Ludolph AC; Storch A
J Neural Transm (Vienna); 2007; 114(11):1395-406. PubMed ID: 17510731
[TBL] [Abstract][Full Text] [Related]
25. miRNA-15a, miRNA-16, miRNA-126, miRNA-146a, and miRNA-223 expressions in autologous hematopoietic stem cell transplantation and their impact on engraftment.
Nowicki M; Szemraj J; Wierzbowska A; Misiewicz M; Małachowski R; Pluta A; Grzybowska-Izydorczyk O; Robak T; Szmigielska-Kapłon A
Eur J Haematol; 2018 May; 100(5):426-435. PubMed ID: 29380440
[TBL] [Abstract][Full Text] [Related]
26. Stem cell transplantation into the intraventricular space via an Ommaya reservoir in a patient with amyotrophic lateral sclerosis.
Baek W; Kim YS; Koh SH; Lim SW; Kim HY; Yi HJ; Kim H
J Neurosurg Sci; 2012 Sep; 56(3):261-3. PubMed ID: 22854595
[TBL] [Abstract][Full Text] [Related]
27. NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.
Berry JD; Cudkowicz ME; Windebank AJ; Staff NP; Owegi M; Nicholson K; McKenna-Yasek D; Levy YS; Abramov N; Kaspi H; Mehra M; Aricha R; Gothelf Y; Brown RH
Neurology; 2019 Dec; 93(24):e2294-e2305. PubMed ID: 31740545
[TBL] [Abstract][Full Text] [Related]
28. Identification of plasma microRNAs as a biomarker of sporadic Amyotrophic Lateral Sclerosis.
Takahashi I; Hama Y; Matsushima M; Hirotani M; Kano T; Hohzen H; Yabe I; Utsumi J; Sasaki H
Mol Brain; 2015 Oct; 8(1):67. PubMed ID: 26497046
[TBL] [Abstract][Full Text] [Related]
29. Intrathecal ciliary neurotrophic factor delivery for treatment of amyotrophic lateral sclerosis (phase I trial).
Penn RD; Kroin JS; York MM; Cedarbaum JM
Neurosurgery; 1997 Jan; 40(1):94-9; discussion 99-100. PubMed ID: 8971830
[TBL] [Abstract][Full Text] [Related]
30. Genome-wide circulating microRNA expression profiling reveals potential biomarkers for amyotrophic lateral sclerosis.
Matamala JM; Arias-Carrasco R; Sanchez C; Uhrig M; Bargsted L; Matus S; Maracaja-Coutinho V; Abarzua S; van Zundert B; Verdugo R; Manque P; Hetz C
Neurobiol Aging; 2018 Apr; 64():123-138. PubMed ID: 29458840
[TBL] [Abstract][Full Text] [Related]
31. Serum microRNAs in sporadic amyotrophic lateral sclerosis.
Freischmidt A; Müller K; Zondler L; Weydt P; Mayer B; von Arnim CA; Hübers A; Dorst J; Otto M; Holzmann K; Ludolph AC; Danzer KM; Weishaupt JH
Neurobiol Aging; 2015 Sep; 36(9):2660.e15-20. PubMed ID: 26142125
[TBL] [Abstract][Full Text] [Related]
32. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis.
Karussis D; Karageorgiou C; Vaknin-Dembinsky A; Gowda-Kurkalli B; Gomori JM; Kassis I; Bulte JW; Petrou P; Ben-Hur T; Abramsky O; Slavin S
Arch Neurol; 2010 Oct; 67(10):1187-94. PubMed ID: 20937945
[TBL] [Abstract][Full Text] [Related]
33. Exposure to cerebrospinal fluid of sporadic amyotrophic lateral sclerosis patients alters Nav1.6 and Kv1.6 channel expression in rat spinal motor neurons.
Gunasekaran R; Narayani RS; Vijayalakshmi K; Alladi PA; Shobha K; Nalini A; Sathyaprabha TN; Raju TR
Brain Res; 2009 Feb; 1255():170-9. PubMed ID: 19109933
[TBL] [Abstract][Full Text] [Related]
34. Astroglia acquires a toxic neuroinflammatory role in response to the cerebrospinal fluid from amyotrophic lateral sclerosis patients.
Mishra PS; Dhull DK; Nalini A; Vijayalakshmi K; Sathyaprabha TN; Alladi PA; Raju TR
J Neuroinflammation; 2016 Aug; 13(1):212. PubMed ID: 27578023
[TBL] [Abstract][Full Text] [Related]
35. Multiple administrations of human marrow stromal cells through cerebrospinal fluid prolong survival in a transgenic mouse model of amyotrophic lateral sclerosis.
Zhang C; Zhou C; Teng JJ; Zhao RL; Song YQ; Zhang C
Cytotherapy; 2009; 11(3):299-306. PubMed ID: 19333801
[TBL] [Abstract][Full Text] [Related]
36. Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis.
Choi MR; Kim HY; Park JY; Lee TY; Baik CS; Chai YG; Jung KH; Park KS; Roh W; Kim KS; Kim SH
Neurosci Lett; 2010 Mar; 472(2):94-8. PubMed ID: 20117176
[TBL] [Abstract][Full Text] [Related]
37. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model.
Kim KS; Lee HJ; An J; Kim YB; Ra JC; Lim I; Kim SU
Cell Transplant; 2014; 23(12):1585-97. PubMed ID: 24070071
[TBL] [Abstract][Full Text] [Related]
38. Systemic treatment with adipose-derived mesenchymal stem cells ameliorates clinical and pathological features in the amyotrophic lateral sclerosis murine model.
Marconi S; Bonaconsa M; Scambi I; Squintani GM; Rui W; Turano E; Ungaro D; D'Agostino S; Barbieri F; Angiari S; Farinazzo A; Constantin G; Del Carro U; Bonetti B; Mariotti R
Neuroscience; 2013 Sep; 248():333-43. PubMed ID: 23727509
[TBL] [Abstract][Full Text] [Related]
39. New insights into the gene expression associated to amyotrophic lateral sclerosis.
Recabarren-Leiva D; Alarcón M
Life Sci; 2018 Jan; 193():110-123. PubMed ID: 29241710
[TBL] [Abstract][Full Text] [Related]
40. Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis.
Siwek T; Jezierska-Woźniak K; Maksymowicz S; Barczewska M; Sowa M; Badowska W; Maksymowicz W
Med Sci Monit; 2020 Dec; 26():e927484. PubMed ID: 33301428
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
